Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer

Launched by ZHEJIANG CANCER HOSPITAL · Oct 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called esketamine can help prevent depression in women who have undergone surgery for ovarian cancer. After cytoreductive surgery, which is a procedure to remove as much of the cancer as possible, some patients may experience feelings of sadness or trouble sleeping. The researchers want to find out if giving a single low dose of esketamine during surgery can reduce these symptoms compared to a placebo, which is just a saline solution that looks like the real medicine but has no effect.

To be eligible for this trial, participants should be women aged 18 to 80 who are scheduled for cytoreductive surgery for ovarian cancer and are generally healthy. Those who are taking certain medications for mental health issues or have other specific health conditions may not qualify. If chosen to participate, women will receive either esketamine or the placebo after they are put to sleep for surgery, and their mood and sleep quality will be assessed afterward. This study is currently looking for participants to help understand how to better support patients after surgery.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • undergoing cytoreductive surgery for ovarian cancer under general anesthesia
• • ASA physical status I-III
• • Ages 18-80 years
• Exclusion Criteria:
• • Patients taking anti-psychotic medications
• • Contraindications to esketamine
• • Language barrier
• • Inability to provide consent